Investment memo on biotech/healthcare market trends and regulatory environment

Investment memo on biotech/healthcare market trends and regulatory environment The passage is a generic market analysis lacking any specific allegations, names, transactions, or controversial actions involving powerful actors. It offers no actionable investigative leads. Key insights: Highlights recent FDA drug approvals and the FDASIA law.; Notes favorable regulatory environment for biotech investors.; Describes contraction in life‑sciences venture capital fundraising since 2008.